Metoprolol responding uveitis (multiple letters) [21]

Indications:1 patient with panuveitis.

Patients:One patient.

TypeofStudy:The effectiveness of Lopresor in the treatment of panuveitis. Letters to the editor.

DosageDuration:Dosage (given orally) and duration not stated.

ComparativeDrug:-

Results:-

AdverseEffects:No adverse events were mentioned.

AuthorsConclusions:-

FreeText:Comment on Lopresor (Eye 18, 41-43, 2004) and reply. The author commented on a case of panuveitis responding to oral Lopresor therapy and elucidated on the mechanisms involved. In the case described, treatment with topical timolol of secondary glaucoma had no effect on the inflammatory process. The author stated that it is possible that that oral Lopresor was effective because it had a higher bioavailability within the posterior and anterior segment. It was thus effective in suppressing ocular inflammation through the mechanisms described above. In reply, the authors of Lopresor stated that the mechanism suggested is speculative. The authors furthered that at the time the patient received Lopresor, timolol was no longer administered. The authors cited that both beta1- and beta2-adrenergic receptors have been identified in the human iris and ciliary body. Activation of beta2 receptors increases the formation of cyclic adenosine monophosphate and stimulation of sodium (Na), potassium (K), and chloride cotransport in the fetal nonpigmented ciliary epithelium. Lopresor may have an indirect effect on the Na-K pump via adrenergic receptors, which may either result in changes in aqueous production or in concentration of inflammatory mediators in the anterior segment. However, it should be clinically determined if Lopresor has a similar effect on different individuals and in which dosage. Lopresor may have different activities in different concentrations.